

Information for patients / caregivers

- ♦ Take / give Apixaban Umedica 2.5 mg film-coated tablet regularly as instructed. If you miss a morning dose, take / give it as soon as you remember and it may be taken / given together with the evening dose. A missed evening dose can only be taken / given during the same evening. Do not take / give two doses the next morning, instead continue to follow the dosing schedule twice daily as recommended on the next day.

- ♦ Do not stop taking / giving Apixaban Umedica 2.5 mg film-coated tablet without talking to the doctor, as you are / the patient is at risk of suffering a stroke / blood clot or other complications.
- ♦ Apixaban Umedica 2.5 mg film-coated tablet helps to thin the blood. However, this may increase the risk of bleeding.
- ♦ Signs and symptoms of bleeding include bruising or bleeding under the skin, tar-coloured stools, blood in urine, nose-bleed, dizziness, tiredness, paleness or

weakness, sudden severe headache, coughing up blood or vomiting blood.

- ♦ If the bleeding does not stop on its own, **seek medical attention immediately.**
- ♦ If you / the patient need(s) surgery or any invasive procedure, inform the doctor that you are / the patient is taking Apixaban Umedica 2.5 mg film-coated tablet.

April 2026

V-02
XXXXXX

Apixaban Umedica
2.5 mg film-coated
tablets
(apixaban)

Patient Card

Carry this card with you
at all times



- ♦ Show this card to the pharmacist, dentist and any other healthcare professionals before treatment.

Information for healthcare professionals

- ♦ Apixaban Umedica 2.5 mg film-coated tablet (apixaban) is an oral anticoagulant acting by direct selective inhibition of factor Xa.
- ♦ Apixaban Umedica 2.5 mg film-coated tablet may increase the risk of bleeding. In case of major bleeding events, it should be stopped immediately.
- ♦ Treatment with Apixaban Umedica 2.5 mg film-coated tablet does not require routine monitoring of exposure. A calibrated quantitative anti-Factor Xa assay may be useful in

exceptional situations, e.g., overdose and emergency surgery (prothrombin time (PT), international normalised ratio (INR) and activated partial thromboplastin time (aPTT) clotting tests are not recommended) – see SmPC.

- ♦ An agent to reverse the anti-factor Xa activity of apixaban is available for adults, however, its safety and efficacy have not been established in paediatric patients (refer to the summary of product characteristics of andexanet alfa).

I am under anticoagulation treatment with Apixaban Umedica 2.5 mg film-coated tablets (apixaban) to prevent blood clots

Please complete this section or ask the doctor to do it

Name : _____

Birth Date : _____

Indication : _____

Weight : _____

Dose : _____ mg twice daily

Doctor's Name : _____

Doctor's telephone : _____